Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 264 articles:
HTML format



Single Articles


    June 2022
  1. MIAN A, Bhattarai N, Sheu M, Ondrejka SL, et al
    Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.
    Br J Haematol. 2022 Jun 22. doi: 10.1111/bjh.18333.
    PubMed    


  2. KAJI FA, Martinez-Calle N, Sovani V, Fox CP, et al
    Rare central nervous system lymphomas.
    Br J Haematol. 2022;197:662-678.
    PubMed     Abstract available


    May 2022
  3. STRUSSMANN T, Glatzki F, Engelhardt M, Mertelsmann R, et al
    Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.
    Br J Haematol. 2022 May 27. doi: 10.1111/bjh.18280.
    PubMed    


  4. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    PubMed     Abstract available


  5. DAWUDI Y, Benali K, Beydon M, Hourseau M, et al
    B-cell lymphoma mimicking relapsing polychondritis.
    Br J Haematol. 2022 May 20. doi: 10.1111/bjh.18220.
    PubMed    


  6. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed     Abstract available


  7. ARMITAGE JO, Gale RP, Jaffe ES
    Lymphoma Nomenclature - What's in a name?
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18063.
    PubMed    


  8. MOMOTOW J, Buhnen I, Trautmann-Grill K, Kobbe G, et al
    Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18231.
    PubMed    


  9. DITTUS C, Miller JA, Wehbie R, Castillo JJ, et al
    Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
    Br J Haematol. 2022 May 4. doi: 10.1111/bjh.18228.
    PubMed    


  10. DIXON JG, Dimier N, Nielsen T, Zheng J, et al
    End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18217.
    PubMed     Abstract available


  11. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available


    April 2022
  12. KUHNL A, Roddie C, Kirkwood AA, Tholouli E, et al
    A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
    Br J Haematol. 2022 Apr 29. doi: 10.1111/bjh.18209.
    PubMed     Abstract available


  13. CALABRETTA E, Guidetti A, Ricci F, Di Trani M, et al
    Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18183.
    PubMed     Abstract available


  14. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
    Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18197.
    PubMed     Abstract available


  15. TANIGUCHI T, Nakayama S, Tanaka H, Rai S, et al
    Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.
    Br J Haematol. 2022 Apr 22. doi: 10.1111/bjh.18208.
    PubMed     Abstract available


  16. MANSON G, Herbaux C, Schiano JM, Casasnovas O, et al
    Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
    Br J Haematol. 2022 Apr 21. doi: 10.1111/bjh.18198.
    PubMed    


  17. EL-GALALY TC, Glimelius I
    Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
    Br J Haematol. 2022 Apr 19. doi: 10.1111/bjh.18199.
    PubMed     Abstract available


  18. ETHIRAJ P, Sasi B, Holder KN, Lin AP, et al
    Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1alpha intersect to regulate angiogenesis in B-cell lymphoma.
    Br J Haematol. 2022 Apr 12. doi: 10.1111/bjh.18196.
    PubMed     Abstract available


  19. ANDERSEN MD, Hamilton-Dutoit S, Modvig L, Vase M, et al
    Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
    Br J Haematol. 2022 Apr 8. doi: 10.1111/bjh.18180.
    PubMed     Abstract available


  20. EKELS A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, et al
    Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.
    Br J Haematol. 2022 Apr 2. doi: 10.1111/bjh.18139.
    PubMed     Abstract available


  21. SHANKAR A, Hall GW, McKay P, Gallop-Evans E, et al
    Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18169.
    PubMed     Abstract available


  22. HESS G, Huttmann A, Witzens-Harig M, Dreyling MH, et al
    A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18161.
    PubMed     Abstract available


  23. PASZKIEWICZ-KOZIK E, Michalski W, Taszner M, Mordak-Domagala M, et al
    Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18166.
    PubMed     Abstract available


  24. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available


  25. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available


    March 2022
  26. TERAS LR, Bertrand KA, Deubler EL, Chao CR, et al
    Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States.
    Br J Haematol. 2022 Mar 29. doi: 10.1111/bjh.18150.
    PubMed     Abstract available


  27. MERCADAL S, Alana M, Barcelo MI, Bruixola G, et al
    Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain.
    Br J Haematol. 2022 Mar 20. doi: 10.1111/bjh.18148.
    PubMed    


  28. GHOLIHA AR, Hollander P, Lof L, Glimelius I, et al
    Checkpoint CD47 expression in classical Hodgkin lymphoma.
    Br J Haematol. 2022 Mar 17. doi: 10.1111/bjh.18137.
    PubMed     Abstract available


  29. BROCKELMANN PJ, Borchmann P
    Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.
    Br J Haematol. 2022 Mar 9. doi: 10.1111/bjh.18130.
    PubMed    


  30. RIISE J, Meyer S, Blaas I, Chopra A, et al
    Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination.
    Br J Haematol. 2022 Mar 7. doi: 10.1111/bjh.18149.
    PubMed     Abstract available


  31. EYRE TA, Jensen P, Booth S, El-Galaly TC, et al
    Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.
    Br J Haematol. 2022 Mar 2. doi: 10.1111/bjh.18104.
    PubMed     Abstract available


  32. PALLETT SJC, Wake R, Youngs J, Pope C, et al
    Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.
    Br J Haematol. 2022;196:1170-1174.
    PubMed    


    February 2022
  33. FOLLOWS GA, Barrington SF, Bhuller KS, Culligan DJ, et al
    Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
    Br J Haematol. 2022 Feb 22. doi: 10.1111/bjh.18083.
    PubMed     Abstract available


  34. ROY I, Smilnak G, Burkart M, Hamilton E, et al
    Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2022 Feb 9. doi: 10.1111/bjh.18054.
    PubMed     Abstract available


  35. SAVANI M, Ahn KW, Chen Y, Ahmed S, et al
    Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
    Br J Haematol. 2022 Feb 2. doi: 10.1111/bjh.18052.
    PubMed     Abstract available


  36. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available


    January 2022
  37. AVIVI I, Luttwak E, Saiag E, Halperin T, et al
    BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Br J Haematol. 2022 Jan 25. doi: 10.1111/bjh.18029.
    PubMed     Abstract available


  38. EL-GALALY TC, Villa D, Cheah CY, Gormsen LC, et al
    Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
    Br J Haematol. 2022 Jan 17. doi: 10.1111/bjh.18016.
    PubMed     Abstract available


  39. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    PubMed    


  40. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    PubMed    


  41. EL-MALLAWANY NK, Curry CV, Allen CE
    Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    Br J Haematol. 2022;196:31-44.
    PubMed     Abstract available


    December 2021
  42. HAEBE S, Keay W, Alig S, Mohr AW, et al
    The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.
    Br J Haematol. 2021 Dec 29. doi: 10.1111/bjh.17990.
    PubMed     Abstract available


  43. REN YM, Shang CY, Liang JH, Yin H, et al
    Prognostic significance of serum immunoglobulin paraprotein in mucosa-associated lymphoid tissue (MALT) lymphoma.
    Br J Haematol. 2021 Dec 28. doi: 10.1111/bjh.18000.
    PubMed     Abstract available


  44. BRANDEFORS L, Sander B, Lundqvist K, Kimby E, et al
    Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
    Br J Haematol. 2021 Dec 27. doi: 10.1111/bjh.18002.
    PubMed     Abstract available


  45. CHIAPPELLA A, Diop F, Agostinelli C, Novo M, et al
    Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
    Br J Haematol. 2021 Dec 23. doi: 10.1111/bjh.17971.
    PubMed     Abstract available


  46. KREISSL S, Voltin CA, Kaul H, Buhnen I, et al
    Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2021 Dec 20. doi: 10.1111/bjh.17997.
    PubMed    


  47. MOLETI ML, Testi AM, Foa R
    Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
    Br J Haematol. 2021 Dec 6. doi: 10.1111/bjh.17979.
    PubMed     Abstract available


    November 2021
  48. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    PubMed    


  49. ZHU Y, Tian S, Xu L, Ma Y, et al
    GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study.
    Br J Haematol. 2021 Nov 21. doi: 10.1111/bjh.17960.
    PubMed     Abstract available


  50. GILLESSEN S, Huttmann A, Vucinic V, Muller H, et al
    Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Gro
    Br J Haematol. 2021 Nov 14. doi: 10.1111/bjh.17878.
    PubMed     Abstract available


  51. GUTIERREZ-GARCIA G, Martinez C, Boumendil A, Finel H, et al
    Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17939.
    PubMed     Abstract available


  52. BANERJEE R, Midha S, Kelkar AH, Goodman A, et al
    Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17945.
    PubMed    


  53. URBAN R, Chow R, Pickles T, Chan M, et al
    The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma.
    Br J Haematol. 2021 Nov 4. doi: 10.1111/bjh.17684.
    PubMed    


  54. LEONCINI L
    Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.
    Br J Haematol. 2021 Nov 2. doi: 10.1111/bjh.17922.
    PubMed    


  55. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available


  56. KAJI D, Kusakabe M, Sakata-Yanagimoto M, Makishima K, et al
    Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
    Br J Haematol. 2021;195:585-594.
    PubMed     Abstract available


  57. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    PubMed    


    October 2021
  58. ZHANG S, Zhang T, Liu H, Zhao J, et al
    Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Br J Haematol. 2021 Oct 19. doi: 10.1111/bjh.17894.
    PubMed     Abstract available


  59. HALLIGAN SJ, Grainge MJ, Martinez-Calle N, Fox CP, et al
    Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
    Br J Haematol. 2021 Oct 18. doi: 10.1111/bjh.17896.
    PubMed     Abstract available


  60. BROCKELMANN PJ
    Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?
    Br J Haematol. 2021 Oct 14. doi: 10.1111/bjh.17891.
    PubMed    


  61. MOORE DC, Soni AC, Hu B, Smith ET, et al
    Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Br J Haematol. 2021 Oct 12. doi: 10.1111/bjh.17886.
    PubMed    


  62. DLOUHY I, Karube K, Enjuanes A, Salaverria I, et al
    Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17858.
    PubMed     Abstract available


  63. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available


  64. ZHANG YC, Wang JN, Ma SY, Cai J, et al
    Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 7. doi: 10.1111/bjh.17849.
    PubMed     Abstract available


  65. RICHTER J, John K, Staiger AM, Rosenwald A, et al
    Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
    Br J Haematol. 2021 Oct 6. doi: 10.1111/bjh.17874.
    PubMed     Abstract available


  66. AMAADOR K, Kersten MJ, Visser O, Brink M, et al
    Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2021 Oct 3. doi: 10.1111/bjh.17856.
    PubMed     Abstract available


  67. GUPTA S, Alexander S, Pole JD, Sutradhar R, et al
    Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 1. doi: 10.1111/bjh.17862.
    PubMed     Abstract available


  68. RUDZKI Z, Starczynski J, Dowds J, Pemberton N, et al
    In situ follicular neoplasia with translocation of BCL6 - a new variant with different immunohistochemical properties.
    Br J Haematol. 2021;195:154.
    PubMed    


  69. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available


    September 2021
  70. TOPP MS, van Meerten T, Houot R, Minnema MC, et al
    Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Sep 29. doi: 10.1111/bjh.17673.
    PubMed     Abstract available


  71. RIEDELL PA, Hamadani M, Ahn KW, Litovich C, et al
    Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
    Br J Haematol. 2021 Sep 28. doi: 10.1111/bjh.17865.
    PubMed     Abstract available


  72. LIU W, Chen X, Fan J, Zhu M, et al
    Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Br J Haematol. 2021 Sep 16. doi: 10.1111/bjh.17729.
    PubMed    


  73. GERHARD-HARTMANN E, Goergen H, Brockelmann PJ, Mottok A, et al
    9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17793.
    PubMed     Abstract available


  74. BASTIDAS-MORA G, Bea S, Navarro A, Gine E, et al
    Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17815.
    PubMed     Abstract available


  75. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    PubMed    


  76. LUTFI F, Holtzman NG, Kansagra AJ, Mustafa Ali M, et al
    The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17738.
    PubMed     Abstract available


  77. BORCHMANN S
    Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17796.
    PubMed    


  78. HODSON DJ
    Diffuse large B-cell lymphoma genetics - simplifying the subtyping.
    Br J Haematol. 2021 Sep 7. doi: 10.1111/bjh.17803.
    PubMed    


  79. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available



  80. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    PubMed    


    August 2021
  81. MORIN RD, Arthur SE, Hodson DJ
    Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17811.
    PubMed     Abstract available


  82. LADDAGA FE, Masciopinto P, Nardelli C, Vacca MP, et al
    In male Hodgkin lymphoma patients, impaired fertility may be improved by non-gonadotoxic therapy.
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17767.
    PubMed     Abstract available


  83. MARTINEZ-CALLE N, Isbell LK, Cwynarski K, Schorb E, et al
    Advances in treatment of elderly primary central nervous system lymphoma.
    Br J Haematol. 2021 Aug 26. doi: 10.1111/bjh.17799.
    PubMed     Abstract available


  84. FJORDEN K, Ekberg S, Kuric N, Smedby KE, et al
    Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
    Br J Haematol. 2021 Aug 25. doi: 10.1111/bjh.17792.
    PubMed    


  85. NOGUCHI K, Ikawa Y, Takenaka M, Sakai Y, et al
    Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Br J Haematol. 2021 Aug 22. doi: 10.1111/bjh.17776.
    PubMed    


  86. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available


  87. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available


  88. EICHENAUER DA, Buhnen I, Kreissl S, Goergen H, et al
    Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17770.
    PubMed     Abstract available


  89. MISHINA T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, et al
    Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
    Br J Haematol. 2021 Aug 10. doi: 10.1111/bjh.17765.
    PubMed     Abstract available


  90. KESAVAN M, Zammar G, McQuillan JT, Macdonald WBG, et al
    Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17758.
    PubMed    


  91. KAJI FA, Martinez-Calle N, Bishton MJ, Figueroa R, et al
    Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17747.
    PubMed     Abstract available


  92. CASTILLO JJ, LaMacchia J, Flynn CA, Sarosiek S, et al
    Plasmablastic lymphoma transformation in a patient with Waldenstrom macroglobulinemia treated with ibrutinib.
    Br J Haematol. 2021 Aug 6. doi: 10.1111/bjh.17759.
    PubMed    


  93. LANDSBURG DJ, Barta SK, Ramchandren R, Batlevi C, et al
    Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
    Br J Haematol. 2021 Aug 2. doi: 10.1111/bjh.17730.
    PubMed     Abstract available


  94. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    PubMed    


  95. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    PubMed    


  96. CORDOBA R, Luminari S, Eyre TA
    The use of frailty assessments in treating older adults with aggressive lymphomas.
    Br J Haematol. 2021;194:677-685.
    PubMed     Abstract available


    July 2021
  97. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available


  98. LYU R, Wang T, Wang Y, Xiong W, et al
    Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17703.
    PubMed     Abstract available


  99. RINALDI F, Marchesi F, Palombi F, Pelosi A, et al
    MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
    Br J Haematol. 2021 Jul 28. doi: 10.1111/bjh.17734.
    PubMed     Abstract available


  100. ALCOCEBA M, Garcia-Alvarez M, Chillon MC, Jimenez C, et al
    Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
    Br J Haematol. 2021 Jul 27. doi: 10.1111/bjh.17719.
    PubMed     Abstract available


  101. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available


  102. OLUWOLE OO, Bouabdallah K, Munoz J, De Guibert S, et al
    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17527.
    PubMed     Abstract available


  103. CHAPMAN JR, Bouska AC, Zhang W, Alderuccio JP, et al
    EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Br J Haematol. 2021 Jul 17. doi: 10.1111/bjh.17708.
    PubMed     Abstract available


  104. OHKI K, Kiyokawa N, Watanabe S, Iwafuchi H, et al
    Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).
    Br J Haematol. 2021 Jul 13. doi: 10.1111/bjh.17639.
    PubMed     Abstract available


  105. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available


  106. HARADA T, Iwasaki H, Muta T, Urata S, et al
    Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Br J Haematol. 2021;194:101-110.
    PubMed     Abstract available


    June 2021
  107. BUSSOT L, Chevalier S, Cristante J, Grange B, et al
    Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
    Br J Haematol. 2021 Jun 21. doi: 10.1111/bjh.17550.
    PubMed     Abstract available


  108. YUE LM, Chau D, Kwong YL, Tse E, et al
    Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
    Br J Haematol. 2021 Jun 13. doi: 10.1111/bjh.17581.
    PubMed    


  109. SIMA A, Hollander P, Baecklund E, Smedby KE, et al
    Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17577.
    PubMed     Abstract available


  110. KOWA JY, Millard T, Goldman A, Sharma RK, et al
    Are treatment response assessment maps (TRAMs) and (18) F-choline positron emission tomography the future of central nervous system lymphoma imaging?
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17632.
    PubMed    


  111. SABATINI PJB, Tremblay-LeMay RMA, Ahmadi Moghaddam P, Delabie JMA, et al
    Marginal zone lymphoma transdifferentiated to histiocytic sarcoma.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17582.
    PubMed    


  112. RUMMEL MJ, Janssens A, MacDonald D, Keating MM, et al
    A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Br J Haematol. 2021;193:1123-1133.
    PubMed     Abstract available


  113. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available


  114. LAKHOTIA R, Roschewski M
    Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Br J Haematol. 2021;193:867-881.
    PubMed     Abstract available


    May 2021
  115. LEE S, Fujita K, Morishita T, Oiwa K, et al
    Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 26. doi: 10.1111/bjh.17554.
    PubMed     Abstract available


  116. GENUARDI E, Romano G, Beccuti M, Alessandria B, et al
    Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Br J Haematol. 2021 May 18. doi: 10.1111/bjh.17519.
    PubMed     Abstract available


  117. SETHI TK, Montanari F, Foss F, Reddy N, et al
    How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sezary syndrome.
    Br J Haematol. 2021 May 14. doi: 10.1111/bjh.17458.
    PubMed     Abstract available


  118. RAMPOTAS A, Wilson MR, Lomas O, Denny N, et al
    Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17513.
    PubMed     Abstract available


  119. HENTRICH M, Muller M, Wyen C, Bogner J, et al
    Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17515.
    PubMed    


  120. ABU SABAA A, Morth C, Hasselblom S, Hedstrom G, et al
    Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.
    Br J Haematol. 2021 May 5. doi: 10.1111/bjh.17206.
    PubMed     Abstract available


  121. WANG C, Althof PA, Bi C, Zhang W, et al
    A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17255.
    PubMed    


  122. BALASUBRAMANIAN S, Wang S, Major C, Hodkinson B, et al
    Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP +/- ibrutinib.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17450.
    PubMed     Abstract available


  123. MA SY, Tian XP, Cai J, Su N, et al
    A prognostic immune risk score for diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17478.
    PubMed     Abstract available


  124. CHIRON D
    Towards ecosystem integration for a better understanding of aggressiveness of B-cell lymphomas.
    Br J Haematol. 2021;193:447-448.
    PubMed    


    April 2021
  125. LAPENA-RODRIGUEZ M, Garces-Albir M, Gadea-Mateo R, Mata-Cano D, et al
    Multiple small bowel perforations during the treatment of primary intestinal extranodal natural killer/T-cell lymphoma, nasal type.
    Br J Haematol. 2021 Apr 29. doi: 10.1111/bjh.17229.
    PubMed    


  126. HABOT-WILNER Z, Frenkel S, Pe'er J
    Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
    Br J Haematol. 2021 Apr 26. doi: 10.1111/bjh.17451.
    PubMed     Abstract available


  127. KHURANA A, Maurer MJ
    Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17433.
    PubMed    


  128. LOH Z, Salvaris R, Chong G, Churilov L, et al
    Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17436.
    PubMed     Abstract available


  129. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available


  130. OVERWEEL AFP, Budel LM, Sandberg Y
    Cutaneous blastoid mantle cell lymphoma.
    Br J Haematol. 2021 Apr 5. doi: 10.1111/bjh.17452.
    PubMed    


  131. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available


  132. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available


  133. POLVERELLI N, Elli EM, Abruzzese E, Palumbo GA, et al
    Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Br J Haematol. 2021;193:356-368.
    PubMed     Abstract available


    March 2021
  134. SILKENSTEDT E, Linton K, Dreyling M
    Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
    Br J Haematol. 2021 Mar 30. doi: 10.1111/bjh.17419.
    PubMed     Abstract available


  135. CHAE H, Cho H, Sa HS, Kim KW, et al
    The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis.
    Br J Haematol. 2021 Mar 29. doi: 10.1111/bjh.17411.
    PubMed    


  136. BOMMIER C, Mauduit C, Fontaine J, Bourbon E, et al
    Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network.
    Br J Haematol. 2021 Mar 25. doi: 10.1111/bjh.17395.
    PubMed     Abstract available


  137. BARRACLOUGH A, Bishton M, Cheah CY, Villa D, et al
    The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma.
    Br J Haematol. 2021 Mar 11. doi: 10.1111/bjh.17404.
    PubMed     Abstract available


  138. KUMAR E, Pickard L, Okosun J
    Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation.
    Br J Haematol. 2021 Mar 10. doi: 10.1111/bjh.17383.
    PubMed     Abstract available


  139. JERKEMAN M
    How should we use ibrutinib in patients with mantle cell lymphoma?
    Br J Haematol. 2021 Mar 10. doi: 10.1111/bjh.17364.
    PubMed    


  140. MILLARD T, Chau I, Iyengar S, El-Sharkawi D, et al
    (18) F-choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma.
    Br J Haematol. 2021 Mar 9. doi: 10.1111/bjh.17374.
    PubMed    


  141. RODRIGUES JM, Nikkarinen A, Hollander P, Weibull CE, et al
    Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
    Br J Haematol. 2021 Mar 8. doi: 10.1111/bjh.17366.
    PubMed     Abstract available


  142. PICARDI M, Giordano C, Della Pepa R, Pugliese N, et al
    Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al. 'How I treat advanced Hodgkin lymphoma - a global view'. Br J Haematol. 2020;190:837-50.
    Br J Haematol. 2021 Mar 4. doi: 10.1111/bjh.17371.
    PubMed    


  143. CONDOM M, Climent F, Fernandez D, Colomer D, et al
    Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience.
    Br J Haematol. 2021;192:1020-1025.
    PubMed     Abstract available


    February 2021
  144. MCCULLOCH R, Lewis D, Crosbie N, Eyre TA, et al
    Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
    Br J Haematol. 2021 Feb 23. doi: 10.1111/bjh.17363.
    PubMed     Abstract available


  145. VELDMAN J, Alsada ZND, van den Berg A, Plattel WJ, et al
    Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
    Br J Haematol. 2021 Feb 23. doi: 10.1111/bjh.17362.
    PubMed     Abstract available


  146. FERRERI AJM, Calimeri T, Lopedote P, Francaviglia I, et al
    MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Br J Haematol. 2021 Feb 23. doi: 10.1111/bjh.17357.
    PubMed     Abstract available


  147. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available


  148. ZHANG XY, Collins GP, Cutter DJ, Eyre TA, et al
    Limited-stage diffuse large B-cell lymphoma: current management and challenges.
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17359.
    PubMed     Abstract available


  149. TROTMAN J, Hokland P
    Correspondence in reference to the previously published Epub manuscript: "Peter Hokland, et al. How I treat advanced Hodgkin lymphoma - a global view. British Journal of Haematology 2020; 190: 837-850." - RESPONSE.
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17370.
    PubMed    


  150. DUGGE R, Wagener R, Mller P, Barth TFE, et al
    Genome-wide DNA methylation analysis along the progression of gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.
    Br J Haematol. 2021 Feb 16. doi: 10.1111/bjh.17193.
    PubMed     Abstract available


  151. XAGORARIS I, Vassilakopoulos TP, Drakos E, Angelopoulou MK, et al
    Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.
    Br J Haematol. 2021 Feb 2. doi: 10.1111/bjh.17352.
    PubMed     Abstract available


  152. STRATI P, Cheng PTM, Steiner RE, Alcedo Andrade PE, et al
    Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
    Br J Haematol. 2021;192:560-567.
    PubMed     Abstract available


  153. MIKHAEEL NG, Cunningham D, Counsell N, McMillan A, et al
    FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Br J Haematol. 2021;192:504-513.
    PubMed     Abstract available


    January 2021
  154. SAMARA A, Shapira S, Lubin I, Shpilberg O, et al
    Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3beta-dependent mechanism.
    Br J Haematol. 2021 Jan 31. doi: 10.1111/bjh.17284.
    PubMed     Abstract available


  155. EICHENAUER DA, Muller H, Elger L, Goergen H, et al
    Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Br J Haematol. 2021 Jan 24. doi: 10.1111/bjh.17327.
    PubMed     Abstract available


  156. KAULEN LD, Erson-Omay EZ, Henegariu O, Karschnia P, et al
    Exome sequencing identifies SLIT2 variants in primary CNS lymphoma.
    Br J Haematol. 2021 Jan 22. doi: 10.1111/bjh.17319.
    PubMed     Abstract available


  157. BOCCOMINI C, Ladetto M, Rigacci L, Puccini B, et al
    A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2021 Jan 21. doi: 10.1111/bjh.17283.
    PubMed     Abstract available


  158. MCMILLAN A, O'Neill AT, Townsend W, Lambert J, et al
    The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
    Br J Haematol. 2021 Jan 10. doi: 10.1111/bjh.17274.
    PubMed    


  159. GHESQUIERES H, Dalban C, Nicolas-Virelizier E, Jardin F, et al
    BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres(dagger).
    Br J Haematol. 2021 Jan 9. doi: 10.1111/bjh.17279.
    PubMed    


  160. CHALLENOR S, Tucker D
    SARS-CoV-2-induced remission of Hodgkin lymphoma.
    Br J Haematol. 2021 Jan 2. doi: 10.1111/bjh.17116.
    PubMed    


  161. RODRIGUEZ-PINILLA SM, Domingo-Domenech E, Climent F, Sanchez J, et al
    Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
    Br J Haematol. 2021;192:82-99.
    PubMed     Abstract available


    December 2020
  162. WONG P, Chambers D, Godbolt D, Lane SW, et al
    Intravascular large B-cell lymphoma presenting with extensive pulmonary embolism.
    Br J Haematol. 2020 Dec 18. doi: 10.1111/bjh.17182.
    PubMed    


  163. BITAR G, Chau I, Wotherspoon A, El-Sharkawi D, et al
    A very rare complication of subdural haematoma: fibrin-associated diffuse large B-cell lymphoma.
    Br J Haematol. 2020 Dec 18. doi: 10.1111/bjh.17239.
    PubMed    


  164. OUN H, Wilson M, Leach M, McKay P, et al
    Central nervous system relapse of primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma.
    Br J Haematol. 2020 Dec 18. doi: 10.1111/bjh.17267.
    PubMed    


  165. MADDOX JM, Horan M, Tafesh L, Shrubsole C, et al
    DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2020 Dec 18. doi: 10.1111/bjh.17278.
    PubMed    


  166. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
    PubMed    


  167. BETRAINS A, Godinas L, Woei-A-Jin FJSH, Rosseels W, et al
    Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
    Br J Haematol. 2020 Dec 13. doi: 10.1111/bjh.17266.
    PubMed    


  168. CHEN MM, Zeng GP, Li J, Fu JH, et al
    High infiltration of CD20(+) B lymphocytes in extranodal natural killer/T-cell lymphoma is associated with better prognosis.
    Br J Haematol. 2020;191:e116-e120.
    PubMed     Abstract available


  169. WONKAM A
    Investigating the missing heritability of fetal haemoglobin level in Africa.
    Br J Haematol. 2020;191:668-670.
    PubMed    


    November 2020
  170. AHMED S, Glover P, Taylor J, Sha C, et al
    Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.
    Br J Haematol. 2020 Nov 29. doi: 10.1111/bjh.17246.
    PubMed     Abstract available


  171. WASTERLID T, Oren Gradel K, Eloranta S, Glimelius I, et al
    Clinical characteristics and outcomes among 2347 patients aged >/=85 years with major lymphoma subtypes: a Nordic Lymphoma Group study.
    Br J Haematol. 2020 Nov 24. doi: 10.1111/bjh.17250.
    PubMed     Abstract available


  172. TURTON P, El-Sharkawi D, Lyburn I, Sharma B, et al
    UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group.
    Br J Haematol. 2020 Nov 22. doi: 10.1111/bjh.17194.
    PubMed     Abstract available


  173. GHILARDI G, Braendstrup P, Chong EA, Schuster SJ, et al
    CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17191.
    PubMed     Abstract available


  174. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
    PubMed    


  175. KIM HD, Cho H, Jeong H, Bang K, et al
    A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum beta2-microglobulin levels.
    Br J Haematol. 2020 Nov 20. doi: 10.1111/bjh.17222.
    PubMed     Abstract available


  176. KHANLARI M, Tang G, Hao S, Gong Y, et al
    Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement.
    Br J Haematol. 2020 Nov 20. doi: 10.1111/bjh.17169.
    PubMed    


  177. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available


  178. MOZAS P, Rivero A, Rivas-Delgado A, Fabregat A, et al
    Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma.
    Br J Haematol. 2020 Nov 16. doi: 10.1111/bjh.17138.
    PubMed     Abstract available


  179. LUTFI F, Holtzman N, Siglin J, Bukhari A, et al
    Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.
    Br J Haematol. 2020 Nov 10. doi: 10.1111/bjh.17121.
    PubMed    


  180. JAIN P, Nastoupil L, Westin J, Lee HJ, et al
    Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
    Br J Haematol. 2020 Nov 5. doi: 10.1111/bjh.17197.
    PubMed    


  181. TROTMAN J
    The road to a cure: are some patients there yet? Commentary on the 2020 UK guidelines for follicular lymphoma.
    Br J Haematol. 2020;191:319-322.
    PubMed    


    October 2020
  182. HUANG HH, Hsiao FY, Chen HM, Wang CY, et al
    Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
    Br J Haematol. 2020 Oct 31. doi: 10.1111/bjh.17142.
    PubMed     Abstract available


  183. ZUCCARO V, Bruno R, Arcaini L
    Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival.
    Br J Haematol. 2020 Oct 31. doi: 10.1111/bjh.17143.
    PubMed    


  184. SHARMAN J, Kabadi SM, Clark J, Andorsky D, et al
    Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.16922.
    PubMed     Abstract available


  185. SCARISBRICK JJ, Bagot M, Ortiz-Romero PL
    The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17117.
    PubMed     Abstract available


  186. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
    PubMed    


  187. CWYNARSKI K, Khwaja J, Montoto S
    'CARMEN': is less, more? Lessons from trials in human immunodeficiency virus-Burkitt lymphoma (HIV-BL).
    Br J Haematol. 2020 Oct 22. doi: 10.1111/bjh.17187.
    PubMed    


  188. FERRERI AJM, Cattaneo C, Lleshi A, Verga L, et al
    A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
    Br J Haematol. 2020 Oct 21. doi: 10.1111/bjh.17188.
    PubMed     Abstract available


  189. MAHAPATRA P, Bashir J, Wilkins B
    A rare diagnosis of Hodgkin lymphoma in the absence of the expected rich inflammatory reaction.
    Br J Haematol. 2020 Oct 20. doi: 10.1111/bjh.17092.
    PubMed    


  190. RENEAU JC, William BM
    Autologous stem cell transplant in first remission for transformed indolent non-Hodgkin lymphoma: additional data to guide practice.
    Br J Haematol. 2020 Oct 16. doi: 10.1111/bjh.17075.
    PubMed    


  191. CHIN CK, Lim KJ, Lewis K, Jain P, et al
    Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
    Br J Haematol. 2020 Oct 16. doi: 10.1111/bjh.17072.
    PubMed     Abstract available


  192. RUNGE HFP, Lacy S, Barrans S, Beer PA, et al
    Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).
    Br J Haematol. 2020 Oct 3. doi: 10.1111/bjh.17132.
    PubMed    


  193. FOX TA, Troy-Barnes E, Kirkwood AA, Chan WY, et al
    Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
    Br J Haematol. 2020;191:194-206.
    PubMed     Abstract available


  194. ST-PIERRE F, Broski SM, LaPlant BR, Ristow K, et al
    Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B.
    Br J Haematol. 2020;191:e41-e43.
    PubMed    


    September 2020
  195. RIEKEN J, Bernard V, Witte HM, Peter W, et al
    Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
    Br J Haematol. 2020 Sep 18. doi: 10.1111/bjh.17083.
    PubMed     Abstract available


  196. MAGGEN C, Dierickx D, Cardonick E, Mhallem Gziri M, et al
    Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.
    Br J Haematol. 2020 Sep 18. doi: 10.1111/bjh.17103.
    PubMed     Abstract available


  197. GIBB A, Pirrie SJ, Linton K, Warbey V, et al
    Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbi
    Br J Haematol. 2020 Sep 14. doi: 10.1111/bjh.17073.
    PubMed     Abstract available


  198. FORDE S, Matthews JD, Jahangiri L, Lee LC, et al
    Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy.
    Br J Haematol. 2020 Sep 3. doi: 10.1111/bjh.17043.
    PubMed     Abstract available


  199. EYRE TA
    Prognostication in Richter syndrome: context is everything.
    Br J Haematol. 2020;190:811-812.
    PubMed    


  200. LUCCHESI A
    Platelets beyond their count, as a key element of the innate immune system in the fight against malaria.
    Br J Haematol. 2020;190:648-649.
    PubMed    


    August 2020
  201. OBR A, Klener P, Furst T, Kriegova E, et al
    A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
    Br J Haematol. 2020 Aug 30. doi: 10.1111/bjh.17063.
    PubMed    


  202. MOCCIA AA, Schar S, Hayoz S, Pirosa MC, et al
    Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
    Br J Haematol. 2020 Aug 17. doi: 10.1111/bjh.17045.
    PubMed     Abstract available


  203. RODRIGUEZ-PINILLA SM, Santonja C, Stewart P, Carvajal N, et al
    Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.
    Br J Haematol. 2020 Aug 11. doi: 10.1111/bjh.17038.
    PubMed    


  204. DE LA CRUZ-BENITO B, Lazaro-Del Campo P, Ramirez-Lopez A, de Soto-Alvarez T, et al
    Managing the front-line treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma during the COVID-19 outbreak.
    Br J Haematol. 2020 Aug 6. doi: 10.1111/bjh.17066.
    PubMed     Abstract available


  205. RODRIGUES JM, Hassan M, Freiburghaus C, Eskelund CW, et al
    p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
    Br J Haematol. 2020 Aug 4. doi: 10.1111/bjh.17023.
    PubMed     Abstract available


    July 2020
  206. GESTRICH CK, Sadri N, Sinno MG, Pateva I, et al
    Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Br J Haematol. 2020 Jul 29. doi: 10.1111/bjh.17000.
    PubMed    


  207. BLENNERHASSETT R, Kwan J, Coyle L, Wong K, et al
    Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres.
    Br J Haematol. 2020 Jul 28. doi: 10.1111/bjh.16998.
    PubMed    


  208. BARNEA SLONIM L, Ma S, Behdad A, Chen Q, et al
    Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.16948.
    PubMed    


  209. LEWIS KL, Chin CK, Manos K, Casey J, et al
    Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Br J Haematol. 2020 Jul 16. doi: 10.1111/bjh.16946.
    PubMed     Abstract available


  210. LIU W, Huang W, Wang M, Lv R, et al
    Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.
    Br J Haematol. 2020 Jul 15. doi: 10.1111/bjh.16951.
    PubMed    


  211. DEL BALDO G, Abbas R, Woessmann W, Horibe K, et al
    Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma.
    Br J Haematol. 2020 Jul 9. doi: 10.1111/bjh.16755.
    PubMed     Abstract available


  212. KUMAR R, Hujairi N, Mohammed K, Attygalle A, et al
    Early interval and serial positron emission tomography-computed tomography (PET-CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma.
    Br J Haematol. 2020 Jul 8. doi: 10.1111/bjh.16919.
    PubMed    


  213. YANG Y, Juskevicius R
    T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.
    Br J Haematol. 2020 Jul 7. doi: 10.1111/bjh.16929.
    PubMed    


  214. JINDAL N, Jain A, Lad D, Prakash G, et al
    Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
    Br J Haematol. 2020 Jul 2. doi: 10.1111/bjh.16921.
    PubMed    


  215. BOOTH S, Collins G
    Epigenetic targeting in lymphoma.
    Br J Haematol. 2020 Jul 1. doi: 10.1111/bjh.16914.
    PubMed     Abstract available


  216. TEPASSE PR, Hafezi W, Lutz M, Kuhn J, et al
    Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature.
    Br J Haematol. 2020;190:185-188.
    PubMed     Abstract available


  217. SHAKIR R, Mikhaeel NG
    A ray of hope in a dire situation: Radiotherapy for progression after chimeric antigen receptor T-cell therapy.
    Br J Haematol. 2020;190:18-19.
    PubMed    


  218. IMBER BS, Sadelain M, DeSelm C, Batlevi C, et al
    Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
    Br J Haematol. 2020;190:45-51.
    PubMed     Abstract available


    June 2020
  219. ASIMAKOPOULOS JV, Angelopoulou MK, Arapaki MP, Kanellopoulos A, et al
    Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin-lymphoma.
    Br J Haematol. 2020 Jun 30. doi: 10.1111/bjh.16903.
    PubMed    


  220. MCNAMARA C, Montoto S, Eyre TA, Ardeshna K, et al
    Update: the investigation and management of follicular lymphoma.
    Br J Haematol. 2020 Jun 24. doi: 10.1111/bjh.16872.
    PubMed    


  221. PRIETO-TORRES L, Trascasa A, Manso R, Machan S, et al
    Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement.
    Br J Haematol. 2020 Jun 24. doi: 10.1111/bjh.16917.
    PubMed    


  222. CHOW VA, Martin PS, Smith SD, Till BG, et al
    Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.
    Br J Haematol. 2020 Jun 22. doi: 10.1111/bjh.16902.
    PubMed    


  223. HOKLAND P, Shah M, David K, Evens A, et al
    How I treat advanced Hodgkin lymphoma - a global view.
    Br J Haematol. 2020 Jun 19. doi: 10.1111/bjh.16587.
    PubMed    


  224. PHILLIPS EH, Illidge TM
    Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?
    Br J Haematol. 2020 Jun 18. doi: 10.1111/bjh.16854.
    PubMed    


  225. YUAN Y, Mapp S, Xu W
    Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor.
    Br J Haematol. 2020 Jun 14. doi: 10.1111/bjh.16813.
    PubMed    


  226. YANG LH, Zhao Y, Maule J, Rapisardo S, et al
    T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classificat
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16886.
    PubMed    


  227. BARR J, Campbell H, McGuire L, Cochrane T, et al
    The flow cytometric characteristics of breast implant-associated anaplastic large cell lymphoma.
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16763.
    PubMed    


  228. MENTER T, Hayoz S, Zucca E, Kimby E, et al
    Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial.
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16876.
    PubMed    


  229. ABRISQUETA P, Delgado J, Alcoceba M, Oliveira AC, et al
    Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16748.
    PubMed     Abstract available


  230. CALVENTE L, Tremblay-LeMay R, Xu W, Chan FC, et al
    Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma.
    Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16777.
    PubMed     Abstract available


  231. MAHALE P, Weisenburger DD, Kahn AR, Gonsalves L, et al
    Anaplastic large cell lymphoma in human immunodeficiency virus-infected people and solid organ transplant recipients.
    Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16778.
    PubMed     Abstract available


  232. BROCKELMANN PJ, von Tresckow B
    Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma.
    Br J Haematol. 2020 Jun 7. doi: 10.1111/bjh.16844.
    PubMed    


    May 2020
  233. KOHORST MA, Nunez CA, Tewari P, Petropoulos D, et al
    Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy.
    Br J Haematol. 2020 May 29. doi: 10.1111/bjh.16761.
    PubMed    


  234. LAUER EM, Waterhouse M, Braig M, Mutter J, et al
    Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
    Br J Haematol. 2020 May 26. doi: 10.1111/bjh.16759.
    PubMed    


  235. TUCKER D, Morley N, MacLean P, Vandenberghe E, et al
    The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
    Br J Haematol. 2020 May 23. doi: 10.1111/bjh.16739.
    PubMed     Abstract available


  236. GLEESON M, Counsell N, Cunningham D, Lawrie A, et al
    Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16691.
    PubMed     Abstract available


  237. MCKAY P, Wilson MR, Chaganti S, Smith J, et al
    The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16866.
    PubMed     Abstract available


  238. CARREAU NA, Armand P, Merryman RW, Advani RH, et al
    Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
    Br J Haematol. 2020 May 19. doi: 10.1111/bjh.16756.
    PubMed     Abstract available


  239. SHIVAROV V, Ivanova M
    Clinical outcomes of composite and sequential B-cell lymphomas with features intermediate between DLBCL/PMBCL and classical Hodgkin Lymphoma from the SEER database.
    Br J Haematol. 2020 May 18. doi: 10.1111/bjh.16728.
    PubMed    


  240. BADAR T, Astle J, Kakar IK, Zellner K, et al
    Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.
    Br J Haematol. 2020 May 16. doi: 10.1111/bjh.16738.
    PubMed    


  241. KIMBY E, Lockmer S, Holte H, Hagberg H, et al
    The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
    Br J Haematol. 2020 May 14. doi: 10.1111/bjh.16692.
    PubMed     Abstract available


  242. MASSARO F, Stepanishyna Y, Manni M, Luminari S, et al
    Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
    Br J Haematol. 2020 May 14. doi: 10.1111/bjh.16714.
    PubMed     Abstract available


  243. LEE S, Fujita K, Morishita T, Negoro E, et al
    Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma.
    Br J Haematol. 2020 May 14. doi: 10.1111/bjh.16743.
    PubMed     Abstract available


  244. SONNEVI K, Wasterlid T, Melen CM, Harrysson S, et al
    Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.
    Br J Haematol. 2020 May 12. doi: 10.1111/bjh.16737.
    PubMed     Abstract available


  245. PEPRAH S, Ogwang MD, Kerchan P, Reynolds SJ, et al
    Mean platelet counts are relatively decreased with malaria but relatively increased with endemic Burkitt Lymphoma in Uganda, Tanzania, and Kenya.
    Br J Haematol. 2020 May 12. doi: 10.1111/bjh.16700.
    PubMed     Abstract available


  246. CALIMERI T, Ferreri AJM
    Prevention of CNS relapse in diffuse large B-cell lymphoma: common sense prevails where science fails.
    Br J Haematol. 2020 May 12. doi: 10.1111/bjh.16719.
    PubMed    


  247. EPPERLA N
    What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid.
    Br J Haematol. 2020 May 9. doi: 10.1111/bjh.16726.
    PubMed    


  248. INOUE H, Rai S, Tanaka H, Espinoza JL, et al
    Tumour-immune microenvironment in duodenal-type follicular lymphoma.
    Br J Haematol. 2020 May 8. doi: 10.1111/bjh.16715.
    PubMed     Abstract available


  249. O'KELLY B, McGettrick P, Angelov D, Fay MP, et al
    Outcome of a patient with refractory Hodgkin's Lymphoma on pembrolizumab, infected with SARS-CoV-2.
    Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16798.
    PubMed     Abstract available


  250. DESTEFANO CB
    Real-world outcomes of post-transplant lymphoproliferative disorder treated with risk-stratified sequential therapy.
    Br J Haematol. 2020;189:398-399.
    PubMed    


  251. MIR F, Wilding C, Mcaddy N, Butterfield N, et al
    Focal splenic lesions in indolent B-NHL: association with high grade transformation and safe percutaneous biopsy.
    Br J Haematol. 2020;189:e157-e160.
    PubMed    


  252. JORDAENS S, Cooksey L, Bonney S, Orchard L, et al
    Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:500-512.
    PubMed     Abstract available


    April 2020
  253. LEE ATJ, Attygale AD, Sharma RK, Iyengar S, et al
    LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy.
    Br J Haematol. 2020 Apr 27. doi: 10.1111/bjh.16679.
    PubMed    


  254. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available


  255. AHMED S, Ghosh N, Ahn KW, Khanal M, et al
    Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
    Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16664.
    PubMed     Abstract available


  256. SMYTH L, Blunt DN, Gatov E, Nagamuthu C, et al
    Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
    Br J Haematol. 2020 Apr 17. doi: 10.1111/bjh.16635.
    PubMed     Abstract available


  257. GOTO H, Hirano N, Inoue M, Takano K, et al
    Immune escape by loss of heterozygosis of HLA genes facilitated the transmission of diffuse large B cell lymphoma from mother to offspring.
    Br J Haematol. 2020 Apr 17. doi: 10.1111/bjh.16662.
    PubMed    


  258. AU-YEUNG RKH, Arias Padilla L, Zimmermann M, Oschlies I, et al
    Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.
    Br J Haematol. 2020 Apr 2. doi: 10.1111/bjh.16578.
    PubMed     Abstract available


  259. TIMMINS MA, Wagner SD, Ahearne MJ
    The new biology of PTCL-NOS and AITL: current status and future clinical impact.
    Br J Haematol. 2020;189:54-66.
    PubMed     Abstract available


  260. KATOR S, Zurko J, Webb BJ, Balatico MA, et al
    Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor T-cell therapy.
    Br J Haematol. 2020;189:e4-e6.
    PubMed    


    March 2020
  261. MARTINEZ-CALLE N, Poynton E, Alchawaf A, Kassam S, et al
    Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Br J Haematol. 2020 Mar 31. doi: 10.1111/bjh.16592.
    PubMed     Abstract available


    February 2020
  262. SCHMELZ JL, Navsaria L, Goswamy R, Chuang HH, et al
    Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report.
    Br J Haematol. 2020;188:e5-e8.
    PubMed    


    January 2020
  263. EYRE TA
    Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas.
    Br J Haematol. 2020;188:202-204.
    PubMed    


    August 2019
  264. PHILIPPE L, Lancar R, Laurent C, Algarte-Genin M, et al
    In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.
    Br J Haematol. 2019 Aug 29. doi: 10.1111/bjh.16176.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: